SCID Labs - EQA Registration

The procurement process for the "SCID Labs - EQA Registration" contract was conducted by NHS England, based in Leeds. This tender is part of the in-service evaluation for the screening of Severe Combined Immunodeficiency (SCID) across seven regional newborn blood spot screening laboratories, including the Newcastle lab. The procurement falls under the health services category and utilised a direct method, classified as "below threshold - without competition."

The process has been completed, with the contract status marked as active. The contract, valued at GBP 18,166.0 net, started on 21 March 2025 and ended on 31 March 2025. This initiative supports the healthcare industry in the United Kingdom, particularly in the region of UKE42.

The tender offers business growth opportunities, especially for large-scale enterprises engaged in health services monitoring and quality control, such as GENQA LTD, the supplier awarded the contract. Businesses that can provide expertise in specialised screening services and support in newborn health diagnostics would find this contract beneficial for expanding their portfolio in health sector services. Although the procurement method was direct and not competitive, similar opportunities in the health services sector might arise, favouring businesses that can demonstrate relevant experience and capabilities in meeting stringent health evaluation criteria.